
Opinion|Videos|June 21, 2024
AUA 2024: Outlining BOND-003 Data for NMIBC Therapy
Author(s)Gary Steinberg, MD, FACS
Expert urologist reviews the BOND-003 study, discussing its design, interim outcomes, safety and efficacy data, and the potential for cretostimogene grenadenorepvec to provide a durable response in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.
Advertisement
Episodes in this series

Video content above is prompted by the following question(s):
- Focusing on the BOND-003 study, please review the study design, key interim outcomes, and safety and efficacy data.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Kari Tikkinen, MD, PhD, discusses POISE-3 findings on tranexamic acid in urologic surgery
4
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
5











